Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments

Reuters

2025/08/04

<a href="https://laohu8.com/S/PRAX">Praxis Precision Medicines</a> Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments

Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system $(CNS)$ disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide $(ASO.AU)$ platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556382335"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556382335\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556382335?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556382335","market":"fut","top_or_hot":-1,"title":"Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide <a href=\"https://laohu8.com/S/ASO.AU\">$(ASO.AU)$</a> platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-04 21:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide <a href=\"https://laohu8.com/S/ASO.AU\">$(ASO.AU)$</a> platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDLvGTPL:1","article_id":"2556382335","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556382335","pubTimestamp":1754313936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system  disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide  platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc.","BK4139":"生物科技"},"translate_title":"Praxis Precision Medicines推出公司演示文稿，重点介绍中枢神经系统疾病治疗的创新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":0.9},"content_text":"Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n    \n\n        Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system $(CNS)$ disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide $(ASO.AU)$ platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}